[go: up one dir, main page]

WO2014035140A3 - Compounds and compositions for modulating histone methyltransferase activity - Google Patents

Compounds and compositions for modulating histone methyltransferase activity Download PDF

Info

Publication number
WO2014035140A3
WO2014035140A3 PCT/KR2013/007728 KR2013007728W WO2014035140A3 WO 2014035140 A3 WO2014035140 A3 WO 2014035140A3 KR 2013007728 W KR2013007728 W KR 2013007728W WO 2014035140 A3 WO2014035140 A3 WO 2014035140A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compositions
methyltransferase activity
histone methyltransferase
modulating histone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/007728
Other languages
French (fr)
Other versions
WO2014035140A2 (en
Inventor
Jae Moon Lee
MinJeong CHOI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kainos Medicine Inc
Original Assignee
Kainos Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kainos Medicine Inc filed Critical Kainos Medicine Inc
Publication of WO2014035140A2 publication Critical patent/WO2014035140A2/en
Publication of WO2014035140A3 publication Critical patent/WO2014035140A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides DOT1L inhibitors, and also methods and use of the compounds of the invention, by themselves or in combination with other therapies, for treating a disease, disorder, or condition.
PCT/KR2013/007728 2012-08-30 2013-08-28 Compounds and compositions for modulating histone methyltransferase activity Ceased WO2014035140A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261694892P 2012-08-30 2012-08-30
US61/694,892 2012-08-30

Publications (2)

Publication Number Publication Date
WO2014035140A2 WO2014035140A2 (en) 2014-03-06
WO2014035140A3 true WO2014035140A3 (en) 2014-05-01

Family

ID=50184543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/007728 Ceased WO2014035140A2 (en) 2012-08-30 2013-08-28 Compounds and compositions for modulating histone methyltransferase activity

Country Status (1)

Country Link
WO (1) WO2014035140A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653711B2 (en) 2015-08-26 2020-05-19 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
US11279970B2 (en) 2017-02-27 2022-03-22 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
US11571437B2 (en) 2019-06-06 2023-02-07 Janssen Pharmaceutica Nv Methods of treating cancer using PRMT5 inhibitors

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517079A (en) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
WO2014039839A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
PT4190786T (en) 2012-12-07 2025-05-29 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
JP2016512239A (en) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinase
JP2016512816A (en) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinase
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
KR102575125B1 (en) 2014-06-05 2023-09-07 버텍스 파마슈티칼스 인코포레이티드 Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
RU2736219C2 (en) 2014-06-17 2020-11-12 Вертекс Фармасьютикалз Инкорпорейтед Method of treating cancer using a combination of chk1 and atr inhibitors
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
ES2872003T3 (en) 2016-09-14 2021-11-02 Janssen Pharmaceutica Nv Spirobyclic inhibitors of the menin-MLL interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109715634B (en) 2016-09-14 2022-09-27 詹森药业有限公司 Fused bicyclic inhibitors of the MENIN-MLL interaction
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
BR112019006414A2 (en) 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv substituted monocyclic and bicyclic ring system carbanucleoside analogs for use as prmt5 inhibitors
KR102513564B1 (en) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. An azepane inhibitor of the menin-MLL interaction
CN109748921B (en) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-tert-butoxycarbonyl-protected heterocyclic compounds, methods for their preparation and methods for preparing C-nucleoside analogs
WO2019110734A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN113454086B (en) * 2019-02-07 2025-03-14 百济神州有限公司 Imidazolo[2,1-F][1,2,4]triazine-4-amine derivatives as TLR7 agonists
CR20220012A (en) 2019-06-12 2022-03-11 Janssen Pharmaceutica Nv NEW SPIROBICYCLIC INTERMEDIATES
MX2022007652A (en) 2019-12-19 2022-09-23 Janssen Pharmaceutica Nv SUBSTITUTED SPIRANCO DERIVATIVES WITH LINEAR CHAIN.
TWI794742B (en) 2020-02-18 2023-03-01 美商基利科學股份有限公司 Antiviral compounds
TWI775313B (en) 2020-02-18 2022-08-21 美商基利科學股份有限公司 Antiviral compounds
AR121356A1 (en) 2020-02-18 2022-05-11 Gilead Sciences Inc ANTIVIRAL COMPOUNDS
CN111484537B (en) * 2020-05-19 2021-10-01 南京工业大学 A method for preparing key intermediates of Remdesivir using a microchannel reaction device
CN111793101B (en) 2020-07-17 2022-09-30 四川大学 Process for the synthesis of C-nucleoside compounds
ES3028915T3 (en) 2021-04-16 2025-06-20 Gilead Sciences Inc Methods of preparing carbanucleosides using amides
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
PE20240654A1 (en) 2021-08-20 2024-04-04 Shionogi & Co NUCLEOSIDE DERIVATIVES AND PRODRUGS THEREOF THAT HAVE INHIBITORY ACTION OF VIRAL GROWTH

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
WO2012012776A1 (en) * 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2009132123A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
WO2012012776A1 (en) * 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMMY E. METOBO ET AL.: "Practical synthesis of l' -substituted Tubercidin C-nucleoside analogs", TETRAHEDRON LETTERS, vol. 53, 2012, pages 484 - 486 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653711B2 (en) 2015-08-26 2020-05-19 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US11318157B2 (en) 2015-08-26 2022-05-03 Janssen Pharmaceutica Nv 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
US10898504B2 (en) 2016-03-10 2021-01-26 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
US11279970B2 (en) 2017-02-27 2022-03-22 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
US11571437B2 (en) 2019-06-06 2023-02-07 Janssen Pharmaceutica Nv Methods of treating cancer using PRMT5 inhibitors

Also Published As

Publication number Publication date
WO2014035140A2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
WO2012082436A3 (en) Modulators of histone methyltransferase, and methods of use thereof
EP2919681A4 (en) Minimally invasive devices, systems and methods for treating the spine
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
GB2502881B (en) Systems, devices, and/or methods for managing implantable devices
EP2892534B8 (en) Compounds and methods for kinase modulation, and indications therefor
WO2012062925A3 (en) Compounds and methods for treating pain
EP3119418A4 (en) Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
EP3043825A4 (en) Gene therapy for the regeneration of chondrocytes or cartilage type cells
PL3074396T3 (en) 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer
EP2724309A4 (en) Social match platform apparatuses, methods and systems
EP3099257A4 (en) Minimally invasive devices, systems and methods for treating the spine
EP2870220A4 (en) Chain drag carbonizer, system and method for the use thereof
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
WO2012116237A3 (en) Heterocyclic compounds and uses thereof
EP2967350A4 (en) Planning, navigation and simulation systems and methods for minimally invasive therapy
IL231591A0 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
HK1209035A1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
SG11201502713QA (en) Compositions, structures and methods for neural regeneration
EP2780341A4 (en) Kinase modulating compounds, compositions containing the same and use thereof
WO2012158672A3 (en) Compounds for use in treatment of mucositis
AU2012240222A8 (en) Methods of treating central nervous system tumors
EP3079680A4 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Legal Events

Date Code Title Description
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 03.07.2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13833601

Country of ref document: EP

Kind code of ref document: A2